Executive Officer Cash Compensation Arrangements
EX-10.19 5 ex10-19.htm EXHIBIT 10.19 ex10-19.htm
Exhibit 10.19
Executive Officer Cash Compensation Arrangements
2010 Salaries
Name | Title | 2010 Salary | |||
Ramin (“Ron”) Najafi, Ph.D. | Chairman and Chief Executive Officer | $ | 356,000 | ||
Thomas J. Paulson | Chief Financial Officer and Treasurer* | $ | 250,000 | ||
Behzad Khosrovi, Ph.D. | Chief Alliance Officer and SVP, Product Development | $ | 238,000 | ||
Mark B. Anderson, Ph.D. | Chief Scientific Officer | $ | 220,000 | ||
Roy J. Wu | Sr. Vice President, Business & Corporate Development | $ | 172,500 |
2010 Bonus Structure
For Dr. Najafi, the 2010 bonus is intended to be calculated as follows:
(40% of base salary at December 31, 2010) x Corporate Performance
For each of Mr. Paulson, Dr. Khosrovi, Dr. Anderson and Mr. Wu, the 2010 bonus is intended to be calculated as follows:
(30% of base salary at December 31, 2010) x [(0.8 x Corporate Performance) + (0.2 x Individual Performance Multiplier)] |
“Corporate Performance” is the percentage determined by adding corporate performance against established goals with respect to research and development (50%), alliance management (25%), new partnerships (15%), and financial performance (10%). Within each category set forth above: if a minimum “threshold” is not achieved with respect to the category, 0% of the percentage with respect to that category is assigned; if a minimum “threshold” is achieved with respect to the category, 50% of the percentage with respect to that category is assigned; if the “target” performance is achieved with respect to the category, 100% of the percentage with respect to that category is assigned; and if “stretch” performance is achieved with respect to the category, 125% of the percentage with respect to that category is assigned. The resulting percentages are then added together which results in the Corporate Performance value.
“Threshold” goals are established generally at levels that are expected to be attainable if management and NovaBay perform as expected, maintaining and enhancing NovaBay’s business as expected, which includes solid performance by the management team and, as appropriate by category, noteworthy progress on clinical trials, business management and financial management.
“Target” goals are established generally at levels that are expected to be attainable only if superior (meaning substantially in excess of expectations) performance is attained by management and NovaBay, which includes superior performance by the management team and, as appropriate by category, superior progress on clinical trials, business management and financial management. It is not expected that all of these goals will be met.
“Stretch” goals are established generally at levels that are expected to be attainable only if outstanding (meaning well in excess of expectations, which may also not be attainable due to factors outside of management’s control despite best efforts) performance is attained by management and NovaBay, which includes outstanding performance by the management team and, as appropriate by category, outstanding progress on clinical trials, business management and financial management. It is extremely unlikely that all of these goals will be met.
“Individual Performance Multiplier” is the percentage determined by the assessment of individual performance, the results of which will result in an Individual Performance Multiplier of 125% (outstanding performance, exceeding objectives), 100% (excellent performance, meeting or exceeding objectives), 75% (acceptable performance, meeting most objectives) or 0% (less than acceptable performance).
The amount and timing of award payments is at the discretion of the Compensation Committee, and the Compensation Committee can modify the amount of the bonus pool at its discretion, and may defer or cancel awards at its discretion.